Overall survival in the pre-testing (solid line) and post-testing (dashed line) groups.

<p>Overall survival in the pre-testing (solid line) and post-testing (dashed line) groups.</p

Sensitivity analysis showing unadjusted non-inferiority test results for overall survival (OS) using different dates to specify pre- and post-testing groups for adoption of KRAS testing.

1<p>Difference in months = Post-testing - Pre-testing; CB: one sided 95% lower confidence bound (LCB). If LCB>−5.0 months, then the post-testing OS is not worse than the pre-testing OS.</p>2<p>Unadjusted p-value for testing inferiority of OS in post- vs. pre-testing group.</p

Characteristics of 1,186 patients diagnosed with metastatic colorectal cancer by group (diagnosis before or after July 1, 2008).

<p>Characteristics of 1,186 patients diagnosed with metastatic colorectal cancer by group (diagnosis before or after July 1, 2008).</p

Treatment patterns for 264 metastatic colorectal cancer patients diagnosed at Stage III by group.

1<p>EGFR inhibitor use alone or in combination with other chemotherapy.</p

Hazard ratios for overall survival by testing group and other characteristics, estimated from multivariable cox proportional hazards regression.

1<p>Two-sided 95% CI from the multivariable Cox model.</p>2<p>One-sided 95% upper confidence bound for post- versus pre-testing group; corresponding p-value <0.001, which rejects the inferiority null hypothesis that OS is worse in the post-testing group than in the pre-testing group.</p

Treatment patterns for 922 metastatic colorectal cancer patients diagnosed at Stage IV by group.

1<p>EGFR inhibitor use alone or in combination with other chemotherapy.</p

Overall survival in the pre-testing and post-testing groups by <i>KRAS</i> test result.

<p><b>A.</b> Overall survival in the pre-testing and post-testing groups among those with <i>KRAS</i> wild-type tumors. <b>B.</b> Overall survival in the pre-testing and post-testing groups among those with <i>KRAS</i> mutations. <b>C.</b> Overall survival in the pre-testing and post-testing groups among those with no <i>KRAS</i> test results (as a result of insufficient or no tissue available for testing).</p